UBS Cuts Bath & Body Works Price Target Citing Persistent Sales Weakness

Key Facts

1UBS lowered its price target for Bath & Body Works to $19 from $22, maintaining a Neutral rating.

2The firm anticipates in-line Q1 earnings amid persistent weak sales trends observed through April.

3TD Cowen also cut its price target for the stock due to deceleration concerns.

UBS has lowered its price target for Bath & Body Works (BBWI) to $19 from $22, maintaining a Neutral rating on the stock. The firm anticipates Q1 earnings to be in line with expectations but highlighted persistent weak sales trends observed through April. Additionally, TD Cowen reduced its price target for the retailer, citing growing concerns over a deceleration in overall performance.

This downward revision comes as the broader retail sector faces headwinds, with U.S. Retail Sales data from May 14, 2026, showing a modest monthly growth of 0.5%, per market data. Compared to peers in the discretionary retail space, the analyst cuts for BBWI reflect caution regarding the company's ability to drive demand in a volatile consumer environment, consistent with recent industry reports showing a pullback in non-essential spending.

Investors are now monitoring the stock's technical levels following these bearish updates, focusing on the upcoming earnings call for clarity on margin sustainability. Looking ahead, scheduled speeches from Federal Reserve officials on May 14, 2026, including Bowman and Williams, may further influence retail sector sentiment through insights into monetary policy and inflation expectations.